0000000000104151
AUTHOR
Monica Notarbartolo Di Villarosa
Plant polyphenols as possible lead compound against hormone-independent multidrug resistant breast cancer.
Alteration of the YY1/RKIP ratio is a frequent event in hepatocellular carcinoma
Effects of curcumin and related analogues on tumor cell lines expressing multiple mechanisms of drug resistance
Analysis of pharmacologic approaches able to restore RKIP function in hepatocellular carcinoma
Pro-oxidant and antitumor effects of curcumin and N-ethylmaleimide in the HA22T/VGH model Overt hepatocellular carcinoma.
Ihnibitor of Apoptosis Proteins (IAPs) as a new possible therapeutic targets in hepatocellular cancer.
Altered Yin Yang 1/RAF-1 kinase inhibitory protein ratio as a possible molecular marker and therapeutic target in hepatocellular carcinoma
New trends in overcoming drug resistance in hepatocellular carcinoma. Looking for pharmacological inhibition of Inhibitory of Apoptosis Proteins (IAPs) by curcumin.
Expression of IAPs (Inhibitory of Apoptosis Proteins) and of their alternative splice variants in hepatocellular carcinoma tissues and cells
IAPs (inhibitors of apoptosis proteins) might have a major role in the apoptotic resistance that marks many cancers. The studies on IAPs in human HCC have focused on survivin or XIAP, indicating that their new or increased expression in this tumor is associated with a more unfavorable prognosis. The present results corroborate these findings, emphasizing the role that the coordinated expression of different IAPs and alternative splice variants might play in the adverse biology of hepatocellular carcinoma.
Alteration of signaling pathways in hepatocellular carcinoma: identification of new pharmacological targets and possible prognosis markers.
Yin Yang 1 and raf-1 Kinase Inhibitory Protein Status in Hepatocellular carcinoma: Future Perspectives
We focus on to the role of the transcription factors NF-κB and Yin Yang 1 (YY1) and of Raf-1 kinase inhibitory protein (RKIP) in hepatocellular carcinoma (HCC). YY1, whose expression is enhanced by NF-κB, favors tumorigenesis. RKIP inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist and there is separate evidence that relevant increases in YY1 and reductions in RKIP occur in HCC. In a recent study on clinical HCC, we found that, indeed, the ratio of YY1 to RKIP mRNA and protein expression is very frequently profoundly inverted in tumors compared with adjacent tissues. Hyperactivation of YY1 in tum…
THE EFFECT OF CYP3A5 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS ON TACROLIMUS DOSE REQUIREMENTS IN CAUCASIAN LIVER TRANSPLANT PATIENTS
Analysis of UGT1A1*28 and DPYD*2A polymorphisms in Sicilians patients with metastatic colorectal cancer treated with Irinotecan and 5-fluorouracil.
Raf-1 Kinase Inhibitor Protein down-regulation in hepatocellular carcinoma: investigation of possible mechanisms
Possible mechanisms of Raf-1 Kinase Inhibitor Protein down-regulation in hepatocellular carcinoma
Antitumor effects of curcumin and of its combination with cisplatin or doxorubicin on human hepatic cancer cells: possible relationship to NF-kB activation and IAP gene expression.
The NF-kB inhibitors curcumin and DHMEQ exert antitumor synergy with cisplatin in hepatic cancer cells. Analysis of relationship to IL-6 production.
Antitumor effects of curcumin, alone or in combination with cisplatin, on hepatic cancer cells. Analysis of their relationship to IL-6 production
Use of herbal products among cancer and transplanted patients in the town of Palermo,Sicily.
Restoration of Raf-1 Kinase Inhibitor Protein levels as a possible therapeutic approach in hepatocellular carcinoma.
DISTRIBUTION OF CYP3A5 AND MDR-1 SINGLE NUCLEOTIDE POLYMORPHISMS IN CAUCASIAN LIVER TRANSPLANT PATIENTS
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors
The aim of the present study was to examine the effects of nonselective (indomethacin) and selective cyclooxygenase-2 (COX-2) inhibitors (NS-398, nimesulide, and CAY10404) on cell growth, cell cycle distribution, and apoptosis in three human hepatocellular carcinoma cell lines (HepG2, HuH-6, and HA22T/VGH) with different characteristics of differentiation and biological behavior. The four COX inhibitors showed a dose-dependent growth-inhibitory effect in all the cell lines. No substantial arrests in the progression of the cells through the cell cycle were observed after treatment of HuH-6 or HA22T/VGH for 48 h with the various inhibitors. On the other hand, there were significant increases …
ELABORATION OF CURCUMIN INTO DIKETONE MODIFIED ANALOGUES DEVOID OF NUCLEOPHILIC ADDITION CAPABILITY; IMPLICATIONS FOR THEIR ANTITUMOR AND CHEMOSENSITIZING ACTIVITIES
Curcumin (CUR), a polyphenolic compound extracted from Curcuma longa L.,can beconsidered as a good lead compound for the design of new drugs for the treatment of cancer and other therapeutic purposes. CUR is endowed with a diketone function, which appears to be important for its antitumor activity: also depending on the dose, the compound may show complex either pro-oxidant or anti-oxidant effects, which both may, at least in part, be linked to this structural moiety. In the lower concentration, "chemopreventive", range, CUR behaves mainly as an antioxidant; at higher concentrations, the a, b-unsaturated 1,3-diketone, as a Michael acceptor, can form adducts with the –SH groups and generate …
"Antitumor effects of the novel NF-kB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production”.
We tested the novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in the hepatic cancer (HCC) HepG2, HA22T/VGH and HuH-6 cells. The sensitivity to the cell growth inhibitory and apoptotic effects of the agent increased along with the levels of constitutively activated NF-kappaB, which were low in HepG2 and higher in HA22T/VGH and HuH-6. In HA22T/VGH, DHMEQ exhibited synergy with cisplatin. In the same cells, DHMEQ exerted dose-dependent decreases in the nuclear levels of activated NF-kappaB and attenuated NF-kappaB activation by cisplatin. It down-regulated Bcl-XL mRNA in a dose-dependent manner and up-regulated that of Bcl-XS. It also decreased interleukin 6 (IL-6), NAIP and, …